Artiva Biotherapeutics, Inc.
NASDAQ: ARTV. Canonical company identity and public leadership record.
US
- Alpha ID
- alpha:company:28d94261-3731-4dc8-8b8e-dda37afdad32
- SEC CIK
- 0001817241
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 16, 2026
- Newest evidence
- Apr 29, 2025
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Fred Aslan, M.D.Since Apr 29, 2025
- Chair
- Not published
- Independent
- 6 / 77 directors published
- Published claims
- 182 distinct sources
- Evidence records
- 80 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 8 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
EXECUTIVE APPOINTED
Christopher P. Horan executive of Artiva Biotherapeutics, Inc., effective 2025-04-29.
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Technical Operations Officer | Christopher P. Horan | Apr 2025 | current | Source reportedE3 |
| President, Chief Executive Officer and Director | Fred Aslan, M.D. | Apr 2025 | current | Source reportedE4 |
| Senior Vice President of Research and Early Development | Heather Raymon, Ph.D. | Apr 2025 | current | Source reportedE5 |
| Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer | Jennifer Bush | Apr 2025 | current | Source reportedE6 |
| Chief Financial Officer and Executive Vice President of Corporate Development | Neha Krishnamohan | Apr 2025 | current | Source reportedE7 |
| Chief Medical Officer | Subhashis Banerjee, M.D. | Apr 2025 | current | Source reportedE8 |
Board of directors
Evidence7 directors published. 6 of 7 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Alison Moore, Ph.D. | Independent | 2024 | None published | Source reportedE2 |
| Brian Daniels, M.D. | Independent | 2020 | None published | Source reportedE2 |
| Daniel Baker, Ph.D. | Independent | 2025 | None published | Source reportedE2 |
| Diego Miralles, M.D. | Independent | 2024 | None published | Source reportedE2 |
| Elizabeth Hougen | Independent | 2021 | None published | Source reportedE2 |
| Fred Aslan, M.D. | Not independent | 2021 | None published | Source reportedE2 |
| Laura Stoppel, Ph.D. | Independent | 2020 | None published | Source reportedE2 |
| Yong-Jun Huh | Independence not published | Not published | None published | Source reportedE2 |
Committees and risk ownership
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Financials and market context
EvidenceGovernance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- CommitteesNot reviewed. Committee mandates show where oversight is delegated.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Christopher P. HoranChief Technical Operations Officercompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:13
- Fred Aslan, M.D.President, Chief Executive Officer and Directorcompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:14, company:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:10
- Heather Raymon, Ph.D.Senior Vice President of Research and Early Developmentcompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:15
- Jennifer BushChief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officercompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:16
- Neha KrishnamohanChief Financial Officer and Executive Vice President of Corporate Developmentcompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:17
- Subhashis Banerjee, M.D.Chief Medical Officercompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:18
- Alison Moore, Ph.D.Directorcompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:5
- Brian Daniels, M.D.Directorcompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:6
- Daniel Baker, Ph.D.Directorcompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:7
- Diego Miralles, M.D.Directorcompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:8
- Elizabeth HougenDirectorcompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:9
- Laura Stoppel, Ph.D.Directorcompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:11
- Yong-Jun HuhDirectorcompany:28d94261-3731-4dc8-8b8e-dda37afdad32:leadership_role:12
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 8 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 29, 2025. Retrieved Apr 28, 2026. Cited by 8 Claims.
- E3sec filing. Published Apr 29, 2025. Retrieved May 15, 2026. Cited by 1 Claim.
- E4sec filing. Published Apr 29, 2025. Retrieved May 15, 2026. Cited by 1 Claim.
- E5sec filing. Published Apr 29, 2025. Retrieved May 15, 2026. Cited by 1 Claim.
- E6sec filing. Published Apr 29, 2025. Retrieved May 15, 2026. Cited by 1 Claim.
- E7sec filing. Published Apr 29, 2025. Retrieved May 15, 2026. Cited by 1 Claim.
- E8sec filing. Published Apr 29, 2025. Retrieved May 15, 2026. Cited by 1 Claim.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 16, 2026- Christopher P. Horan executive of Artiva Biotherapeutics, Inc., effective 2025-04-29.
- Fred Aslan, M.D. executive of Artiva Biotherapeutics, Inc., effective 2025-04-29.
- Heather Raymon, Ph.D. executive of Artiva Biotherapeutics, Inc., effective 2025-04-29.
- Jennifer Bush executive of Artiva Biotherapeutics, Inc., effective 2025-04-29.
- Neha Krishnamohan executive of Artiva Biotherapeutics, Inc., effective 2025-04-29.
- Subhashis Banerjee, M.D. executive of Artiva Biotherapeutics, Inc., effective 2025-04-29.
- Daniel Baker, Ph.D. seat on Artiva Biotherapeutics, Inc., effective 2025-01-01.
- Alison Moore, Ph.D. seat on Artiva Biotherapeutics, Inc., effective 2024-01-01.
- Diego Miralles, M.D. seat on Artiva Biotherapeutics, Inc., effective 2024-01-01.
- Elizabeth Hougen seat on Artiva Biotherapeutics, Inc., effective 2021-01-01.
- Fred Aslan, M.D. seat on Artiva Biotherapeutics, Inc., effective 2021-01-01.
- Brian Daniels, M.D. seat on Artiva Biotherapeutics, Inc., effective 2020-01-01.
- Laura Stoppel, Ph.D. seat on Artiva Biotherapeutics, Inc., effective 2020-01-01.

